Ken Griffin’s Curanex Pharmaceuticals CURX Stock Holding History

Ken Griffin’s Portfolio CURX Stock Details CURX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.9K	Sell	50,559 -53,719	-52%	-$20.2K	﹤0.01%	12618
2025 Q4	$34.5K	Buy	104,278 +40,211	+63%	+$22.1K	﹤0.01%	12175
2025 Q3	$46.1K	Buy	+64,067	New	+$290K	﹤0.01%	12244

Other funds holding CURX

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ken Griffin's CURX Position: Q1 2026 in Review

Ken Griffin reduced its Curanex Pharmaceuticals (CURX) stake by 52% in Q1 2026, selling an estimated $20.2K and leaving 50,559 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12618.

Ken Griffin first reported a position in CURX in Q3 2025 and has held it in 3 quarters since. The position peaked at $46.1K in Q3 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

Ken Griffin held 50,559 shares of Curanex Pharmaceuticals worth $25.9K as of Q1 2026.
Ken Griffin sold 53,719 Curanex Pharmaceuticals shares in Q1 2026, an estimated $20.2K.
Curanex Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12618 holding.
Ken Griffin first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
Ken Griffin's Curanex Pharmaceuticals position peaked at $46.1K in Q3 2025.
8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.